Nearly a decade after his passing, Stanford neurosurgeon Paul Kalanithi's bestselling memoir "When Breath Becomes Air" continues to inspire. His wife Lucy shares how the book, written during his battle with lung cancer, has touched countless lives. med.stanford.edu/news/insights/…

Congrats!

Congrats Srinivas Viswanathan!

Writing is thinking | Nature Reviews Bioengineering nature.com/articles/s4422…

Big congrats!

Congrats on Mayo Clinic Urology published study led by Drs Veronica R Bravo and Josep Domingo-Domenech discover that nucleoplasm-residing nucleoporins drive #ProstateCancer progression & immune evasion by switching on oncogenic signaling from deep within the nucleus! vist.ly/3z88z

Congratulations to first authors Kirthika, VJ and Peiyao 👏 👏 👏! Great collaborative effort with Zhu Lab and Veronica R Bravo labs. Also thanks to reviewers and editors Cancer Discovery for positive and constructive feedback.

I’ve signed up to ride my bike this August with Fred Hutch Obliteride, a fundraiser for Fred Hutch Cancer Center. I’m working hard to raise money for cancer prevention, detection, treatment, and cures. secure.fredhutch.org/goto/omarmian

Sneak peek at the future of personalized AI-guided treatment algorithms of mUC by Dr. Bishoy M. Faltas #bcantt25 Bladder Cancer Advocacy Network

Targeting lineage plasticity in #ProstateCancer with EZH2 inhibitor mevrometostat. Michael Schweizer Fred Hutch Cancer Center sits down with Oliver Sartor, MD Mayo Clinic diving into #mevrometostat—an #EZH2 inhibitor tackling lineage plasticity in #mCRPC. Adding it to enzalutamide slashed

Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in Nature Medicine Matt Galsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model

Congrats Matt Galsky Andrea Necchi et al. elegant methodology & interesting hypotheses! Kudos for pursuing biomarker analyses in the context of a positive trial! Bladder Cancer Advocacy Network Joshua Meeks Hsieh Lab David McConkey Uromigos Ashish M. Kamat, MD, MBBS Matt Milowsky Shilpa Gupta Sarah P. Psutka MD MS Dr. Bishoy M. Faltas

Researchers at Fred Hutch invented a new screening method called ReLiC — described recently in the journal nature Methods — that solves that problem using CRISPR-Cas9, the Nobel-prize winning gene-editing technology. Read more: bit.ly/4lecXTu

Recently published: Patterns of #HER2 Expression in Metastatic Prostate & Urothelial Cancers: Implications for HER2-Targeted Therapies, by Hyun Jung Lee et al. doi.org/10.1158/2767-9… Petros Grivas @hsiehlab UW Dept. of Laboratory Medicine and Pathology 🔬 Fred Hutch Cancer Center #ProstateCancer #UrothelialCancer #OpenAccess

Kudos to our Fred Hutch Cancer Center UW Dept. of Laboratory Medicine and Pathology 🔬 team Ruben Raychaudhuri Hsieh Lab et al. for this important study: T-DXd pan-tumor approval: Test for HER2 using gastric Ca scoring system Cancer Research Communications OncoAlert Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO Yüksel Ürün Shilpa Gupta Uromigos Dr. Tom Lynch Vadim Koshkin MD

Her2 it is expressed in a lot of cell types, but not all cell types. Implications for emerging treatments for GU cancers. Congrats to Ruben Raychaudhuri for this piece of work. Petros Grivas Fred Hutch Cancer Center

Read our latest in Journal of Clinical Investigation - Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas jci.org/articles/view/… led by Yaniv Kazansky and #HelenMueller Memorial Sloan Kettering Cancer Center

If you’re interested in the interplay between regulation (or mis-regulation) of RNA processing and cancer, please check out the 2025 FASEB RNA Processing in Cancer meeting Oct 5-9 2025 in Sacramento CA! events.faseb.org/event/RNA-Proc…

So excited to see published after 7+ years of hard teamwork! Ali Khaki wrote protocol at Vail AACR we designed, open, accrued, monitored single center trial in a population in need! Kudos Ruben Raychaudhuri who led the poster & paper! Hsieh Lab Sarah P. Psutka MD MS Fred Hutch Cancer Center Dr. Tom Lynch

Important piece of work by Petros Grivas and Ruben Raychaudhuri Fred Hutch Cancer Center. Especially in the wake of the NIAGARA trial. 1) Bigger studies are needed to see if this signal holds. 2) Correlative studies will be interesting to determine how and why this happens.